Glucocorticoid-induced osteoporosis

Hosp Pract (1995). 1995 Aug 15;30(8):45-9, 52-3; discussion 53-6. doi: 10.1080/21548331.1995.11443242.

Abstract

High-dose treatment of more than three months' duration reduces bone mass, regardless of the patient's age, sex, or race. Because bone loss is most severe during the first six to 12 months of treatment, prophylaxis to preserve bone--with calcium, vitamin D, a bisphosphonate, and exercise--should begin as soon as the clinical situation permits rather than after the disease has been brought under control.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Aged
  • Calcium / therapeutic use
  • Combined Modality Therapy
  • Diphosphonates / therapeutic use
  • Drug Therapy, Combination
  • Exercise Therapy
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects*
  • Humans
  • Iatrogenic Disease / prevention & control
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / drug therapy
  • Osteoporosis / chemically induced*
  • Osteoporosis / prevention & control
  • Polymyalgia Rheumatica / complications
  • Polymyalgia Rheumatica / drug therapy
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Time Factors
  • Vitamin D / therapeutic use

Substances

  • Diphosphonates
  • Glucocorticoids
  • Vitamin D
  • Calcium
  • Prednisone